Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associ...

Full description

Bibliographic Details
Main Authors: Zarir F Udwadia, Jai B Mullerpattan, Canchi Balakrishnan, Luca Richeldi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Lung India
Subjects:
Online Access:http://www.lungindia.com/article.asp?issn=0970-2113;year=2015;volume=32;issue=1;spage=50;epage=52;aulast=Udwadia